Popular weight-loss drugs following bariatric surgery may offer additional cardiovascular benefits, research indicates

Medications like semaglutide and liraglutide may help to reduce the risk of heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with obesity and diabetes following bariatric surgery who did not achieve sufficient weight loss and diabetes control, according to new research presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May).